RxDoctor Payments DataLook up a doctor →

Matthew Sincock, MD

Infectious Disease · Wilmington, NCNPI 1851550255

Payments from drug & device makers

$274,307in general payments, 2019–2025

Across 746 payments — averaging $367.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$186K
  • GSK$80K
  • Gilead$2K
  • AbbVie$1K
  • Merck$942
  • Melinta Therapeutics, LLC$655
  • plus $4K from 25 others
$3,348in research payments, 2019–2025

Across 10 payments — averaging $334.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3K

What the payments were for

  • Consulting fees$17,71018%
  • Speaking & faculty fees$60,37562%
  • Travel & lodging$5,8916%
  • Food & beverage$13,16914%
  • Education$2270%
  • Gifts$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,307 in reported general payments places this provider in the 90th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$123,429
Medicare patients
268
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala92$358,383
DovatoDolutegravir Sodium/Lamivudine120$350,149
TivicayDolutegravir Sodium93$235,844
DescovyEmtricitabine/Tenofov Alafenam91$202,151
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf27$128,239
OdefseyEmtricitab/Rilpiviri/Tenof Ala34$124,883
CabenuvaCabotegravir/Rilpivirine13$86,544
JulucaDolutegravir/Rilpivirine13$43,706
Vancomycin Hcl50$6,793
Darunavir23$4,690
Daptomycin13$2,804
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$2,255
Ritonavir24$2,111
CeftriaxoneCeftriaxone Sodium49$1,829
Cefadroxil78$1,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Juluca$186,373$716,243239 claims
GileadBiktarvy, Descovy$1,589$560,534183 claims
Janssen Products, LPSymtuza$99$128,23927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →